Metformin Teva B.V.

Metformin Hydrochloride, the active ingredient in Metformin Teva B.V., is a biguanide presented as an unknown strength oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving insulin sensitivity and lowering hepatic glucose production.

GNH USA supplies Metformin Teva B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hydrochloride is a biguanide that acts on glucose metabolism to control hyperglycaemia in several related conditions.

- Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Prediabetes (impaired glucose tolerance): lowers the risk of progression to type 2 diabetes when used with lifestyle measures. - Polycystic ovary syndrome: helps restore ovulatory function by decreasing insulin resistance and lowering circulating androgen levels.

Metformin Hydrochloride is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: when combined with other glucose‑lowering agents. - Anaemia: unexplained reduction in haemoglobin. - Pancreatitis: inflammation of the pancreas.

Metformin Hydrochloride requires careful monitoring in specific patient groups and clinical situations.

- Renal function monitoring: assess creatinine clearance before initiation and periodically thereafter. - Hepatic assessment: evaluate liver function tests prior to therapy. - Lactic acidosis risk: avoid use in patients with conditions predisposing to hypoxia or severe infection. - Elderly patients: start at lower doses and monitor tolerance closely. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Hydrochloride may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates lactic acidosis. - Carbamazepine: reduces metformin exposure. - Rifampicin: decreases metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors: can affect renal function, requiring dose adjustment. - Diuretics: may impair renal clearance of metformin. - NSAIDs: increase risk of renal impairment. - Digoxin: monitor for additive effects on renal function.